PFE · News · 20261104N

Product Demand Trends

PFIZER INC · 2026-11-04 · Importance 58 · Surprise 56 · No source text

Pfizer’s launched and acquired products generated $3.8 billion in Q3 2026 revenue, up 32% operationally. Padcev, Nurtec, and Lorbrena contributed $255 million, $135 million, and $114 million, respectively, while acquired products grew 37% operationally. Nurtec grew 33% operationally, and Pfizer also cited contributions from Eliquis and the Vyndaqel family; COVID-19 products and the Prevnar family declined.

Key facts

• Pfizer's launched and acquired products generated $3.8 billion in Q3 2026 revenue, up 32% operationally. source
• Pfizer's acquired products grew 37% operationally in Q3 2026; its legacy Seagen portfolio grew 39% year over year in the US. source
• Pfizer's Nurtec grew 33% operationally in Q3 2026. source
• Pfizer reported that non-COVID products grew 7% operationally in Q3 2026, offset by lower COVID-19 product revenues. source
• Pfizer's COVID-19 products and Prevnar family declined in Q3 2026. source

Impact estimates